Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy
Hak‐Mien Quah(Memorial Sloan Kettering Cancer Center), Martin R. Weiser(Memorial Sloan Kettering Cancer Center), Mithat Gönen(Memorial Sloan Kettering Cancer Center), R. Landmann(Johns Hopkins University), Jinru Shia(Memorial Sloan Kettering Cancer Center), Philip B. Paty(Memorial Sloan Kettering Cancer Center), Deborah Schrag(Dana-Farber Brigham Cancer Center), W. Douglas Wong(Memorial Sloan Kettering Cancer Center), Joanne F. Chou(Memorial Sloan Kettering Cancer Center), Larissa K. Temple(University of Rochester Medical Center), José G. Guillem(University of North Carolina at Chapel Hill)
Cited by 255
Related Papers
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Diagnosis and Treatment of Metastatic Colorectal Cancer
|JAMA|2021|2.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k